SCHEMBL6239280

SCHEMBL6239280

CC(=O)OCCc1c(NC(=O)c2cc3cc([N+](=O)[O-])ccc3o2)cc(NC(=O)OC(C)(C)C)c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAOB P27338 5/20 0.42
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
F12 P00748 1/20 0.39
CYP24A1 Q07973 1/20 0.38
MAPT P10636 3/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
MMP2 P08253 1/20 0.37
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
USP2 O75604 1/20 0.36
MAOA P21397 1/20 0.35
POLB P06746 2/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6245467 0.91 NPC1 (0.48) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL6243892 0.91 NPC1 (0.48) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL6245336 0.90 NPC1 (0.44) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL6263396 0.86 RAB9A (0.47) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL5792560 0.83 NPC1 (0.42) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL6244773 0.81 RAB9A (0.46) NPC1RAB9AMAOBMEN1KMT2A
SCHEMBL7256063 0.78 RAB9A (0.44) NPC1RAB9AMAPTGAAHPGD
SCHEMBL6183967 0.77 RAD52 (0.41) NPC1RAB9AKMT2AMAPTLMNA
SCHEMBL6237416 0.76 RAB9A (0.45) NPC1RAB9AMAPTLMNAGAA
SCHEMBL5794764 0.76 NPC1 (0.44) NPC1RAB9AMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320522-B1 COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS TAIHO PHARMACEUTICAL CO LTD (JP) 2005-11-23 EP disclosed
US-6660742-B2 Alkylation therapy; anticancer agent TAIHO PHARMACEUTICAL CO. LTD. (JP) 2003-12-09 US disclosed
US-20030073731-A1 Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins MEDIMMUNE LIMITED (GB) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073731-A1 Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins DDB1, ERCC2, SSU72 NPC1 2541/4885RAB9A 3639/4885MAOB 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.